RELEASE DATE:  January 7, 2002

RFA:  RFA-AR-02-006


National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  February 21, 2002
Application Receipt Date:       March 21, 2002



The National Institute of Arthritis and Musculoskeletal and Skin Diseases 
(NIAMS) and the National Heart, Lung, and Blood Institute(NHLBI) invite 
applications for basic and clinical research on heritable disorders of 
connective tissue.  Heritable disorders of connective tissue are rare 
diseases caused by abnormalities in structural macromolecules and other 
molecules involved in their biosynthesis, processing, and degradation, 
regulatory molecules, cell membrane receptors and other molecules involved in 
signaling, and membrane transporters that reside wholly or partly in the 
extracellular matrix.  A few hundred clinically defined conditions are 
gathered under this umbrella, and as many as 1 million people in the United 
States may have a heritable disorder of connective tissue.  This announcement 
requests applications on mechanisms of disease pathogenesis and development 
of novel therapeutic strategies.  Collaborative research, involving 
investigators with expertise in various scientific disciplines and clinical 
specialties is encouraged.  The applications may be for individual research 
projects (R01) or for exploratory/developmental grants (R21).  The objective 
of the exploratory/developmental mechanism (R21) is to encourage applications 
from individuals who are interested in testing innovative or conceptually 
creative ideas that are scientifically sound and may advance our 
understanding of these disorders.


The Public Health Service (PHS) is committed to achieving the health 
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas. This RFA is related to 
several objectives, particularly those listed in the chapter "Arthritis, 
Osteoporosis, and Chronic Back Conditions and Heart Diseases and Stroke." 
Potential applicants may obtain a copy of "Healthy People 2010" at


Applications may be submitted by domestic and foreign, for-profit and non-
profit organizations, public and private, such as universities, colleges, 
hospitals, laboratories, units of State and local governments, and eligible 
agencies of the Federal government. Faith-based organizations are eligible to 
apply for these grants. Racial/ethnic minority individuals, women, and 
persons with disabilities are encouraged to apply as Principal Investigators.


This RFA will use the R01 (investigator-initiated research project grant) and 
the R21 (exploratory/developmental research grant) award mechanisms. The R01 
application instructions have been modified to reflect "MODULAR GRANT" and 
"JUST-IN-TIME" streamlining efforts being examined by the NIH. Complete and 
detailed instructions and information on Modular Grant applications can be 
found at  
Responsibility for the planning, direction, and execution of the proposed 
project will be solely that of the applicant. Future unsolicited competing 
continuation applications will compete with all investigator-initiated 
applications and be reviewed according to the customary peer review 
procedures. The anticipated award date is September 30, 2002.

R21 Applications. Exploratory/developmental studies are not intended for 
large scale undertakings nor to support or supplement ongoing research.  
Instead, investigators are encouraged to explore the feasibility of an 
innovative research question or approach which may not be justifiable through 
existing research to compete as a standard research project grant (e.g., 
R01), and to develop a research basis for a subsequent application through 
other mechanisms, i.e., R01, P01.

Exploratory/developmental (R21) grants, may not exceed $75,000 per year in 
direct costs.  The total project period for an R21 application submitted in 
response to this RFA may not exceed three years for the NIAMS and two years 
for the NHLBI.  These grants are non-renewable and continuation of projects 
developed under the R21 program will be through the traditional unsolicited 
(R01 or P01) grant programs.

Investigators proposing to conduct small, pilot/toxicity clinical trials are 
advised to review the NIAMS and NHLBI guidelines for preparation of clinical 
trial applications and the NIAMS and NHLBI guidelines for Data and Safety 
Monitoring Boards

R01 Applications.  Because the nature and scope of the research proposed in 
response to this RFA may vary, it is anticipated that the size of an award 
will vary also.   Modular budgeting procedures apply for grants up to 
$250,000.  Specific R01 application instructions have been modified to 
reflect "Modular grant" and "Just-in-time" streamlining efforts.  For the 
NHLBI, the total project period must not exceed  four years.  Complete 
instructions and information on Modular Grants can be found at


The estimated funds available for the first year of support for the program 
are $1,000,000 for NIAMS and $1,000,000 for NHLBI.

Because the nature and scope of the research proposed may vary, it is 
anticipated that the size of each award will also vary.  Although the 
financial plans of the NIAMS and the NHLBI provide support for this program, 
awards pursuant to this RFA are contingent upon the availability of funds and 
the receipt of a sufficient number of meritorious applications. At this time, 
it is not known if this RFA will be reissued.



Heritable disorders of connective tissue are rare diseases that result from 
abnormalities in many types of molecules, including structural 
macromolecules, enzymes involved in their biosynthesis, processing, and 
degradation, regulatory molecules like growth factors and transcription 
factors, cell membrane receptors and other molecules involved in signaling, 
and membrane transporters.  As a result, the number of disorders that can be 
considered to involve alterations in the structure, synthesis, degradation, 
or signaling pathways of molecules that reside wholly or partly in the 
extracellular matrix includes a few hundred clinically defined conditions.  
Some abnormalities may give rise to severe phenotypes, while others may 
produce milder symptoms.  Examples of such diseases are Marfan's and Ehler-
Danlos syndromes which can lead to life-threatening vasculopathies and 
intracardiac malformations.

In November, 2000, the NIAMS, the NIH Office of Rare Diseases, the March of 
Dimes, the Coalition for Heritable Disorders of Connective Tissue, and the 
Foundation for Basic Cutaneous Research sponsored the 3rd Workshop on 
Heritable Disorders of Connective Tissue at the NIH.  The purpose of the 
workshop was to review current knowledge in this research area focusing on 
approaches to the question of pathogenesis of heritable disorders of 
connective tissue at all levels (genetic approaches, biochemical approaches, 
developmental approaches, and cell-matrix interactions).  By focusing on 
multidisciplinary approaches and common themes, the goals were to stimulate 
new collaborations between researchers interested in different diseases and 
more rapid progress in this area.  By focusing on pathogenesis of heritable 
disorders of connective tissue, the goal was to gain that additional 
knowledge, beyond the first step of identification of disease genes, required 
for the development of new therapies.

The Workshop participants voiced a high priority for the continued 
development of mouse models of human diseases with in-depth studies on 
mechanisms of disease pathogenesis and the development of new therapeutic 
agents.  They also described the potential for the development of stem cell 
therapies and the development of prenatal and preimplantation gene screening.  
Some broad areas of recommended research directions include, but are not 
limited to:

o  Pathogenesis of connective tissue using human and mouse models

o  Identification of secondary mechanisms of pathogenesis

o  Determinants of phenotypic variability in mice and humans; the role of 
stochastic variations in genotype-phenotype correlations

o Use of existing and development of new mouse models to understand 
pathological sequence of events and to develop therapies

o  Development of in vitro approaches to fully exploit mouse models and test 
in vitro/in vivo correlations

o  Hierarchy of the assembly and diversification of the extracellular matrix

o  Quantitative determination of molecular interactions of matrix molecules

o  Protein-protein interactions both inside and outside the cell

o  Role of the extracellular matrix in tissue assembly and homeostasis; 
matrix assembly as a complex whole; regulators of matrix assembly

o  Role of the ECM in morphogenesis and cell differentiation

o  Development of therapies for connective tissue repair and regeneration


It is the policy of the NIH that women and members of minority groups and 
their sub-populations must be included in all NIH-supported clinical research 
projects unless a clear and compelling justification is provided indicating 
that inclusion is inappropriate with respect to the health of the subjects or 
the purpose of the research. This policy results from the NIH Revitalization 
Act of 1993 (Section 492B of Public Law 103-43).

All investigators proposing clinical research should read the AMENDMENT "NIH 
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical 
Research - Amended, October, 2001," published in the NIH Guide for Grants and 
Contracts on October 9, 2001 
a complete copy of the updated Guidelines are available at  
The amended policy incorporates: the use of an NIH definition of 
clinical research; updated racial and ethnic categories in compliance with 
the new OMB standards; clarification of language governing NIH-defined Phase 
III clinical trials consistent with the new PHS Form 398; and updated roles 
and responsibilities of NIH staff and the extramural community.  The policy 
continues to require for all NIH-defined Phase III clinical trials that: a) 
all applications or proposals and/or protocols must provide a description of 
plans to conduct analyses, as appropriate, to address differences by 
sex/gender and/or racial/ethnic groups, including subgroups if applicable; 
and b) investigators must report annual accrual and progress in conducting 
analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.


It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted or supported by 
the NIH, unless there are scientific and ethical reasons not to include them. 
This policy applies to all initial (Type 1) applications submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the Inclusion of Children as Participants in 
Research Involving Human Subjects that was published in the NIH Guide for 
Grants and Contracts, March 6, 1998, and is available at the following URL 

Investigators also may obtain copies of these policies from the program staff 
listed under INQUIRIES. Program staff may also provide additional relevant 
information concerning these policies.


All applications and proposals for NIH funding must be self-contained within 
specified page limitations. Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no obligation 
to view the Internet sites. Reviewers are cautioned that their anonymity may 
be compromised when they directly access an Internet site.


The Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances. Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) 
cited publicly and officially by a Federal agency in support of an action 
that has the force and effect of law (i.e., a regulation) may be accessed 
through FOIA. It is important for applicants to understand the basic scope of 
this amendment. NIH has provided guidance at:

Applicants may wish to place data collected under this RFA  in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time. If so, the application should 
include a description of the archiving plan in the study design and include 
information about this in the budget justification section of the 
application. In addition, applicants should think about how to structure 
informed consent statements and other human subjects procedures given the 
potential for wider use of data collected under this award.


Prospective applicants are asked to submit, by February 21, 2002, a letter of 
intent that includes a descriptive title of the proposed research; the name, 
address, and telephone number of the Principal Investigator; the identities 
of other key personnel and participating institutions; and the number and 
title of this RFA. Although a letter of intent is not required, is not 
binding, does not commit the sender to submit an application, and does not 
enter into the review of a subsequent application, the information that it 
contains allows IC staff to estimate the potential review workload. The 
letter of intent is to be sent (e-mail, fax or post) to Dr. Tommy Broadwater 
at the address listed under INQUIRIES.


The PHS 398 research grant application instructions and forms (rev. 5/2001) 
at must be used in 
applying for these grants. This version of the PHS 398 is available in an 
interactive, searchable format. For further assistance contact GrantsInfo, 
Telephone 301/710-0267, Email:


The research plan is limited to 25 pages for R01s and 10 pages for R21 
applications (exclusive of cited references).  Applications that exceed the 
page limit will be returned without review.  An appendix may be included in 
the application; however, the appendix is not to be used to circumvent the 
page limit of the research plan.


Applications requesting up to $250,000 per year in direct costs must be 
submitted in a modular grant format.  The modular grant format simplifies the 
preparation of the budget in these applications by limiting the level of 
budgetary detail.  Applicants request direct costs in $25,000 modules.  
Section C of the research grant application instructions for the PHS 398 
(rev. 5/2001) at 
includes step-by-step guidance for preparing modular grants.  Additional 
information on modular grants is available at

The RFA label available in the PHS 398 (rev. 5/2001) application form must be 
affixed to the bottom of the face page of the application.  Type the RFA 
number on the label.  Failure to use this label could result in delayed 
processing of the application such that it may not reach the review committee 
in time for review.  In addition, the RFA title and number must be typed on 
line 2 of the face page of the application form and the YES box must be 
marked. The RFA label is also available at:

Submit a signed, typewritten original of the application, including the 
Checklist, and three signed, photocopies, in one package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express mail or courier service)
At the time of submission, two additional copies of the application must be 
sent to Dr. Tommy Broadwater at the address listed under INQUIRIES.

Applications must be received by the application receipt date listed in the 
heading of this RFA. If an application is received after that date, it will 
be returned to the applicant without review. The Center for Scientific Review 
(CSR) will not accept any application in response to this RFA that is 
essentially the same as one currently pending initial review, unless the 
applicant withdraws the pending application. The CSR will not accept any 
application that is essentially the same as one already reviewed. This does 
not preclude the submission of substantial revisions of applications already 
reviewed, but such applications must include an Introduction addressing the 
previous critique.


Upon receipt, applications will be reviewed for completeness by the NIH 
Center for Scientific Review and for responsiveness by NIAMS and NHLBI staff; 
those judged to be incomplete or not in the format specified in this RFA will 
be returned to the applicant without review. Those considered to be non-
responsive will be returned without review.

Applications that are complete and responsive to the RFA will be evaluated 
for scientific and technical merit by an appropriate peer review group 
convened by NIAMS  in accordance with the review criteria stated below.  As 
part of the initial merit review, a process will be used by the initial 
review group in which all applications will receive a written critique but 
only those applications deemed to have the highest scientific merit will be 
discussed, assigned a priority score, and receive a second level review by 
the National Advisory Councils of the NIAMS and the NHLBI.

Review Criteria

The five criteria to be used in the evaluation of grant applications are 
listed below.  To put those criteria in context, the following information is 
contained in instructions to the peer reviewers.

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  The 
reviewers will comment on the following aspects of the application in their 
written critiques in order to judge the likelihood that the proposed research 
will have a substantial impact on the pursuit of these goals.  Each of these 
criteria will be addressed and considered by the reviewers in assigning the 
overall score weighting them as appropriate for each application.  Note that 
the application does not need to be strong in all categories to be judged 
likely to have a major scientific impact and thus deserve a high priority 
score.  For example, an investigator may propose to carry out important work 
that by its nature is not innovative but is essential to move a field forward.

1. Significance.  Does this study address an important problem? If the aims 
of the application are achieved, how will scientific knowledge be advanced?  
What will be the effect of these studies on the concepts or methods that 
drive this field?

2. Approach.  Are the conceptual framework, design, methods, and  analyses 
adequately developed, well integrated, and appropriate to the aims of the 
project?  Does the applicant acknowledge potential problem areas and consider 
alternative tactics? 

3. Innovation.  Does the project employ novel concepts, approaches or 
method?  Are the aims original and innovative? Does the project challenge 
existing paradigms or develop new methodologies or technologies? 

4. Investigator.  Is the investigator appropriately trained and well suited 
to carry out this work?  Is the work proposed appropriate to the experience 
level of the principal investigator and other researchers (if any)?

5. Environment.  Does the scientific environment in which the work will be 
done contribute to the probability of success?  Do the proposed experiments 
take advantage of unique features of the scientific environment or employ 
useful collaborative arrangements?  Is there evidence of institutional 

In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

The adequacy of plans to include both genders, minorities and their 
subgroups, and children as appropriate for the scientific goals of the 
research.  Plans for the recruitment and retention of subjects will 
also be evaluated.

The reasonableness of the proposed budget and duration in relation to 
the proposed research

The adequacy of the proposed protection for humans, animals or 
the environment, to the extent they may be adversely affected by 
the project  proposed in the application
The personnel category will be reviewed for appropriate staffing based 
on the requested percent effort. The direct costs budget request will 
be reviewed for consistency with the proposed methods and specific 
aims. For modular grant applications, any budgetary adjustments 
recommended by the reviewers will be in $25,000 modules. The duration 
of support will be reviewed to determine if it is appropriate to ensure 
successful completion of the requested scope of the project.
Letter of Intent Receipt Date:    February 21, 2002
Application Receipt Date:         March 21, 2002
Peer Review Date:                 TBA
Council Review:                   September, 2002
Earliest Anticipated Start Date:  September 30, 2002
Award criteria that will be used to make award decisions include:
o scientific merit (as determined by peer review)
o availability of funds
o programmatic priorities
Inquiries concerning this RFA are encouraged. The opportunity to 
clarify any issues or questions from potential applicants is welcome. 
Direct inquiries regarding programmatic issues to:
Cartilage and Connective Tissue
Dr. Bernadette Tyree
45 Center Drive, Room 5AS-25H
Bethesda, MD  20892-6500
Telephone:  (301) 594-5032
FAX:  (301) 594-4543
Muscle Biology
Dr. Richard W. Lymn
45 Center Drive, Room 5AS-49E
Bethesda, MD  20892-6500
Telephone:  (301) 594-5128
FAX:  (301) 480-4543
Skin Diseases
Dr. Alan N. Moshell
45 Center Drive, Room 5AS-25L
Bethesda, MD  20892-6500
Telephone:  (301) 594-5017
FAX:  (301) 480-4543
Bone Biology
Dr. William J. Sharrock
45 Center Drive, Room 5AS-37A
Bethesda, MD  20892-6500
Telephone:  (301) 594-5055
FAX:  (301) 480-4543
Cardiovascular Diseases
Dr. Stephen S. Goldman
Vascular Biology Research Program
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Rockledge 2
6701 Rockledge Drive, MSC 7956
Bethesda, MD  20892-7956
Telephone:  (30) 435-0560
FAX:  (301) 480-2858
Direct review inquiries to:
Dr. Tommy Broadwater
Review Branch 
45 Center Drive, Natcher Bldg. Rm. 5A25U
Bethesda, MD  20892-6500
Telephone:  (301) 594-4953
FAX:  (301) 480-4543
Direct inquiries regarding fiscal matters to:
Melinda Nelson
Grants Management Officer
45 Center Drive, Natcher Bldg. Rm. 5A49F
Bethesda, MD  20892-6500
Telephone:  (301) 594-3535
FAX:  (301) 480-5450
Beckie Chamberlin
Grants Operations Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Rockledge 2
6701 Rockledge Drive, MSC 7926
Bethesda, MD  20892-7926
Telephone  (301) 435-0166
FAX:  (301) 480-3310
This program is described in the Catalog of Federal Domestic Assistance 
No. 93.846.  Awards are made under authorization of the Public Health 
Service Act, Title IV, Part A (Public Law 78-410), as amended by Public 
Law 99-158, 42 USC 241 and 285) and administered under PHS grants 
policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74.  This 
program is not subject to the intergovernmental review requirements of 
Executive Order 12372 or Health Systems Agency review.
The PHS strongly encourages all grant and contract recipients to 
provide a smoke-free workplace and promote the non-use of all tobacco 
products.  In addition, Public Law 103-227, the Pro-Children Act of 
1994, prohibits smoking in certain facilities (or in some cases, any 
portion of a facility) in which regular or routine education, library, 
day care, health care or early childhood development services are 
provided to children.  This is consistent with the PHS mission to 
protect and advance the physical and mental health of the 
American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.